Novartis Czech Republic's total assets reached CZK 1,898 mil at the end of 2017, up 9.89% compared to the previous year.
Current assets amounted to CZK 1,770 mil, or 93.3% of total assets while cash stood at CZK 0 mil at the end of 2017.
By contrast, total debt reached CZK 51.2 mil at the year-end, or 2.70% of total assets, while the firm's equity amounted to CZK 652 mil. As a result, net debt stood at CZK 51.2 mil at the end of 2017 and accounted for 7.85% of equity.
Net debt against equity is down 8.80 pp from five years ago (16.7%). The ratio against EBITDA decreased from 0.696x seen in 2012 to 0.371x.
The company’s cost of funding amounted to 15.6% in 2017, down 12.0 pp compared to the average over the last 5 years.
You can see all the company’s data at Novartis Czech Republic profile, or you can download a report on the company in the report section.
Helgi Library 
